SP Group A/S (SPG) Earnings Call Transcript
November 18, 2026
Earnings Call Speaker Segments
Hello, and good afternoon. I’m speaking on behalf of H.C. Andersen Capital, and I’d like to welcome everyone to this presentation of the Q3 2026 report from SP Group, which came out yesterday. My name is Rasmus Køjborg, and it’s a pleasure to welcome CEO Lars Bering and CFO Allan Jepsen; they said they would walk us through the figures and the latest highlights, so a warm welcome to both of you. Before I hand things over, I also want to extend a warm welcome to everyone who registered for today’s presentation. As usual, you can put your questions in the chat room, and if writing in English doesn’t feel comfortable, feel free to write in Danish and I’ll translate them. Please don’t hesitate to ask any questions to the management team here at SP Group. If you’d like to watch the presentation again, it will be published afterward on various platforms. With that, I’ll turn off my camera and then come back for the Q&A, but for now I’ll leave it to you, Lars and Allan.
Thanks a lot, Rasmus, and welcome as we present the results for the third quarter of 2026. I'm Lars Bering, the CEO of SP Group.
My name is Allan Jepsen, CFO of SP Group.
Along with Søren Ulstrup, I’m part of the executive board. For anyone joining us for the first time, we’ll begin today with a brief overview of SP Group, and then we’ll walk through the third quarter and the first nine months of 2026, a period in which we’ve achieved a number of records. Allan and I will present together during today’s session and fill in details for each other as we go. SP Group provides technical plastic solutions. These may be products for the healthcare sector or components that remain inside our customers’ products for many years. 77% of our revenue is generated by our sub-supplier business, while 23% comes from our own products. These are plastic products sold under their own brands worldwide. We have slightly more than 3,000 employees across 35 factories in a global footprint. 18% of the raw material used in our production consists of recycled materials, and our target is to reach 25% in 2030.
Healthcare makes up our biggest product group, accounting for 35% of revenue. Cleantech comes next at 29%, then foodtech at 14%, and the other category at 22%. Every one of those four groups grew in '26, and we'll return to that point later on in this presentation.
Correct. SP Group is set up as a set of independent units, and each one owns its technology as well as its customers. The light green units shown on the left-hand side of this slide are those that have products of their own, among them Ergomat, SP Medical, and MedicoPack. Over on the right-hand side you find the sub-supplier units, ranging from injection molding at SP Moulding to composites and polyurethanes at Tinby. A new name has also appeared on the page since August: OGM now stands next to SP Moulding within injection molding. This model is decentralized by design, since we want decisions taken near the customers so that agility and efficiency stay high. The group's role is to get the units to assist one another with purchasing, sharing knowledge, and cross-selling. Idé-Pro and OGM are two very strong examples of that this year. Allan, could you show us where we are in the world?
Yes. As of today, we have operations in 13 countries worldwide, and we produce goods in 10 of those. The most recent addition is the United Kingdom, which came in through the OGM acquisition in August. The chart displayed shows how sales broke down in '25. In '26, that picture hasn't changed. Outside Denmark, 71% of revenue was generated during the first nine months. Geographically, growth in '26 has been broad. Sales to customers outside Denmark increased 35%, while sales to Danish customers climbed 39%. So in other words, no single market is one we depend on. Turning to our workforce, nearly seven in 10 employees are now based outside Denmark.
So now we get to the highlights, and I'll begin with the biggest one. Nine months in—nine months—we've already made more money than in all of last year. Profit before tax stands at 350 million versus 345 million for the entire prior year. Our third quarter was the strongest quarter this company has ever had. Revenue climbed 43% to 938 million, and organic growth came in at 23.9%. But you have to view that growth against the dynamic we experienced in last year's second half, when a number of orders shifted from the third quarter into the fourth. We're also making more money on the revenue today. Profit before tax increased 58%, and the EBT margin reached 10.9% compared with 9.9% in last year's third quarter; back in August, I walked you through what we've been working on. As of today, we can report that a great deal of it is operational. OGM is now part of the group. We've devoted considerable time to introducing the organization to one another, the sales team in particular, and collaboration between the companies is already very good. Idé-Pro is generating cross-selling and new projects for existing SP Group customers, and in Poland, SP Meditech has taken 1,700 square meters of new controlled production environment into use; there's more news as well: with Idé-Pro's help, Ergomat has set up local production and distribution in India, and we've already shipped the first orders. Last, we've enlarged the share buyback program by 40 million Danish and extended it to the end of April next year—to the end of April next year. Turning to our own products, growth has been good. Sales were up 20.3% to 677 million. That's the highest level we've reached after three quarters. The advance is driven by TPI's ventilation products and the ergonomic products from Ergomat. Sales of pharmaceutical packaging from MedicoPack and our guidewires from SP Medical are flat, just as we mentioned in August. Two things to keep in mind: own products are frequently sold within larger projects, so individual quarters can fluctuate, and Ergomat's new production in India is meant to bring us closer to customers in Asia, where we expect growth going forward. Sub-supplier revenue makes up the biggest share of our growth. We sold for 2 billion and 211 million during the first nine months; that's 652 million, or 41.8%, above last year. Some of the growth stems from acquisitions. Idé-Pro is included for the full period, and OGM from August 19. Acquisitions don't account for everything, though. Group organic growth was 21%, and a substantial portion comes from sub-supplier revenue; the companies we already own have also performed strongly during the period. What pleases me most, though, is that we continue to win new work with both existing and new customers. Activity levels in the factories are high—are high. Next come the product groups.
Right. Every one of our four product groups has seen growth during the first nine months of 2026. As Lars mentioned a moment ago in the highlights, total revenue is up 36%. Looking at how the four groups have developed, healthcare has accelerated. The healthcare product group grew 18% in the first half of '26 and 31% in the third quarter. So far this year, growth in this category comes to 22% overall. Healthcare revenue stands at 1 billion and 25 million for the first nine months. Cleantech is holding steady at 40% growth, in the quarter as well as in the first half of 2026. The foodtech category is up 48% year-to-date; growth in the third quarter was 28%, so the pace here is a bit slower than in the spring. The other category has risen 51% year-to-date, reaching revenue of 623 million Danish kroner. Growth has been strong all year and is partly driven by the acquisition of Idé-Pro and OGM.
Thanks, Allan. Back in August we laid out the reasoning behind buying OGM. Now I want to walk you through how the first three months have played out. What we've observed has borne that out. OGM is a solidly run business, started in 1962, with 190 employees across two factories; we've spent the time introducing the sales teams to one another and kicking off the integration. Customer overlap between OGM and the rest of SP Group is small, and the cross-selling opportunities look very strong. Some first projects are already underway. OGM has also started buying from Idé-Pro, which is building the first tool for OGM. The thinking is unchanged from August. This gives SP Group a new bridgehead into the UK. The products are more advanced, box-build is a competence, and OGM's customers gain access to a global production platform.
Lars has covered the main points. Now I'll walk you through some of the numbers in more detail. Third-quarter revenue increased 43.2% to 938 million. Organic growth accounted for 23.9% of that, while 19.3% came from buying Idé-Pro and OGM. EBITDA climbed 42.1% to 179 million. The EBITDA margin stood at 19.1%, compared with 19.3% a year earlier. Keep in mind that in Q3 '26 we spent 5 million related to the OGM acquisition. The EBIT margin came in at 10.9%, which is 1 percentage point above the same period last year. Turning to the year-to-date figures through the end of September, revenue reached 2 billion 888 million. That's 36.1% higher than last year and just 60 million below the full-year revenue for all of '25. Organic growth makes up more than half, at 21%, with acquisitions adding 15.1%. EBITDA was up 38% to 567 million, and the year-to-date EBITDA margin is 19.9% versus 19.7% last year. EBIT increased 47.7% to 398 million, and profit before tax was up 52.6% to 350 million. All three margins exceed last year's levels, and the EBIT margin for the year-to-date period is 12.1% compared with 10.8% last year, which actually places us in the middle of this year's guidance range. Looking at cash flows from operating activities across the first nine months, we generated 410 million, which is 83 million more than last year. That came through growth, which required 55 million more in working capital. Earnings per share increased 58% to 23.42 Danish kroner; that's above the full-year figure for '25, which was 22.13 Danish kroner. Net interest-bearing debt at the end of September was 1 billion 497 million, up 37 million since the start of the year. The increase is mainly due to the OGM acquisition and the debt assumed with it. Gearing, defined as net interest-bearing debt divided by EBITDA, is 2 times versus 2.4 at the turn of the year, and we expect it below 2.0 by the end of this year. Equity at the end of September was 1 billion 962 million, and the equity ratio at the end of September was 44%. Lars, could you take us through the long-term development?
Right, since one quarter alone can’t capture the full picture of SP Group, that’s the reason we consistently present the long-term trend in our materials. Revenue across the last 12 months came to 3.7 billion. A decade earlier, in 2016, the figure stood at 1.5 billion — roughly two and a half times higher over 10 years, which works out to an average growth rate of 9.6%. That growth has arrived through two routes: organically, and via more than 20 acquisitions. Idé-Pro and OGM are the latest ones, and both of them sit in the final bar. For 2030 our ambition is a level of 4.5 billion, and we are moving toward that goal very well indeed. We haven’t just become bigger — we also earn more on our revenue. EBITDA over the past 12 months is 754 million. Margin has climbed from 13% in 2016 to 20.3% across the past 12 months. The four drivers behind that increase remain the same as always, and they continue to deliver. Let me give you a current example of each one. Own products: Ergomat now manufacture in India, where we have begun distributing in Asia. In Eastern Europe, new MedTech production space has been brought into use in Poland. Automation: we apply this across all our factories, with robots in production, AGVs for internal transportation, and most recently we’ve implemented AI agents to handle administrative work. The value chain: thanks to OGM, we can build finished products with electronics, including testing and packaging. The same trend holds for EBIT, which the same drivers affect. EBIT has risen almost fourfold over the past 10 years, from 123 million in 2016 to 466 in the past 12 months. Margin stands at 12.5% versus 8% in 2016. Lastly, we are very pleased to have earned 350 million in the first nine months. That exceeds the whole of 2025.
Yes. Now, turning to the outlook for '26: during this year, we've raised our revenue guidance on two occasions, the latest being in August with the OGM acquisition. As of yesterday, we tightened that guidance by lifting the low end of the range. Our current expectation is revenue growth of 26% to 30%, versus the 24% to 30% we had before; this equates to revenue at a level of 3.7 to 3.8 billion. Acquisitions should contribute 16% to 17% percentage points of that growth. Looking at the quarterly pattern on the right side of this slide, revenue in the second and third quarters of '25 came in lower, in part since tariff challenges pushed projects into the fourth quarter. That means the fourth quarter of '26 will be compared against last year's biggest quarter, in which some revenue stemmed from projects shifted out of earlier quarters; across '26, revenue has been more evenly high in all three quarters, supported by organic growth as well as the Idé-Pro and OGM acquisitions. We still anticipate an EBITDA margin at a level of 19% to 21%, along with an EBIT margin of 11% to 13%.
Thank you, Allan. So if you take away three points from what we've shared today, here they are. Number one, this was our strongest third quarter on record. Our EBIT margin went up, even with the OGM acquisition and a smaller share coming from own products. Number two, the growth we've posted is broad-based; it's coming out of all four of our product groups, and it's coming from our own products as well as our sub-supplier business, plus there's been solid organic growth too. Number three, the initiatives we put in motion are now up and running. OGM sits within SP Group, Idé-Pro is generating cross-selling, production in Poland is now in use, and Ergomat is manufacturing in India. As Allan mentioned, we narrowed the outlook for the year by lifting the bottom of the range, and yesterday we expanded the share buyback program. Thanks for listening; we're ready now to take your questions.
Thanks a lot, Lars and Allan. Sure, let's take a few of the questions. As came up earlier today, one is about your outlook and the growth implied for Q4. The way it's put here, Q4 implies revenue growth of 0% to 14%, and for the full year acquisitions add 16% to 17% percentage points; that would mean negative organic growth in Q4. Is that entirely down to the comparison base from the project postponement in 2025, or are you actually seeing a real slowdown in Q4?
This is the first item you brought up, and it matches what we're observing. Factories remain very busy and the order book looks solid, that's the first part. Beating a quarter such as the one we posted in quarter four of last year is difficult.
Thank you. Then here's another question that also came up earlier today, and it's about your long-term ambitions. When will you update the targets for 2030? They appear as though they'll be achieved in '27 or '28, and certainly not in 2030.
There's a very, very strong chance we could exceed 4.5 billion in 2030. You're absolutely right on that point. Should we manage to get there ahead of 2030, then naturally we'll revisit those ambitions and revise them. What matters to look at, I think, is also what we've stated, which is that we're aiming for a growth rate of 6% to 9% across the years, and hopefully we can do more if larger acquisitions become possible; that's the goal we're pursuing.
Thanks, and I have another question about your US facilities. I believe those are also listed in the appendix, if I'm not mistaken. It ought to be in there, since there's a question that relates to this. Let me take a quick look here. How is the US production facility coming along, and where does capacity utilization stand at the moment?
Things are going quite well at the US plant. Revenue has risen the way we expected, and we're still hard at work putting a lot of new tasks in place in the factory. That factory isn't full yet, but the plans we have for it over the coming years will fill it up.
Alright, and here’s another question about your acquisition activity. From what we can see here, you’ve completed more than 15 acquisitions since 2015, and then as we move to your global footprint on this slide, the question is this: since 2015 you have made over 15 acquisitions. What capability or geography does the group still lack that you would want to add? We’ve heard you’ve been expanding in India, but are there other areas you’d like to expand into?
As you can see on this map, the bulk of our revenue comes from Europe, and naturally we'd like to grow in the US and Asia too, since our customers want reliable suppliers who offer a solid regional production platform. On the capabilities side, yes, there remain some niche areas we'd like to expand into, but those sit in the smaller area.
Good. The OGM acquisition is one example of the capabilities you're expanding into, since there was also a question about that. Let me just check. One moment. The UK is a completely new production market for you. How much harder is it to operate there after Brexit when it comes to customs, certification, and labor costs?
Taking everything together, what we’ve found is that the OGM business in Oxford is, in many respects and culturally speaking, quite similar to ours. They operate a production setup with some highly advanced products for their customers, and they’ve been building those skills over the years. Our aim is to take these box-build capabilities and apply them in our other factories — in Europe, and also in Asia and the US. For us, the potential here is that OGM’s customers can have production in either Eastern Europe or the US or in India with a very simple setup, while still being controlled by OGM. That, we believe, is where the real benefit lies. We currently have no plans for huge shipments across borders. What we’re seeing is that more and more of our customers would rather the components they need be produced very close to where they actually need them.
Yes, and I have a follow-up question about this box-build, since it's a new capability for the group, and you mentioned that you'll roll it out at other factories. Is there any timeline for that? I believe you've only owned OGM for roughly three months, so do you still need some time to learn more about this capability?
We are in progress of planning that part. Yeah.
Good. Next, I have a handful of questions about your margins in Q3. Would you expand on how margins developed in Q3: gross margin, EBITDA, EBIT? Margins came down versus the first half of 2026. What mainly drove that development?
On an EBIT margin basis, we've still delivered at last year's level—in fact, slightly better, as I mentioned. Looking at Q3 against the two quarters before it, own products made up a smaller share, and that tends to mean a thinner margin. So the share of own products did have an effect on Q3.
Good, and one more thing on that: in Q3, how much of the organic growth was driven by price, and how much came from volume?
It is by far mostly related to volume.
Good. Then another question about your global footprint, since someone here is asking: you now run 33 factories in nine countries. When does that footprint start to become a problem in terms of cost and complexity, and are there any sites you'd think about consolidating?
Consolidation opportunities are something we constantly evaluate. That said, you should keep in mind that across these 35 factories worldwide, the work differs a great deal from one site to another; some of what we run involves small niche operations staffed by highly specialized people, so simply merging everything into a single large factory wouldn't be sensible, since we don't think that would genuinely lift our margin. Thanks to our decentralized structure and strong local management teams, we've been able to make quick, sound decisions near the customers and also achieve an efficient factory setup.
Alright, thanks. Now I have a question about your own products. Your own products bring in better margins compared with subcontracting work. If the mix continues moving toward subcontracting, where does the group EBIT margin end up settling over time?
Naturally, that hinges on how events unfold. There is no intention on our side for own products to represent a small portion. Our aim is for our own products to expand at a quicker pace than overall growth. Still, we managed to bring in two excellent businesses, Idé-Pro and OGM, and we think these can take SP Group forward in a strongly favorable way. We'll keep creating new own products, and naturally we're also seeking acquisitions that come with own products so as to broaden that area of the business.
Okay, and now a question about your products group, which we also covered in the Danish presentation earlier. Looking at that other part, it's at roughly 22% now; it grew about 50% on a nine-month basis, and in fact, I believe on a Q3 basis alone it was almost 100%, at 97.8%. What exactly is behind that, and how big is the defense exposure today?
Naturally, acquiring OGM and Idé-Pro does affect that product category. If you dig into the details of the other category, defense doesn't appear to be meaningfully above where it stood in prior years.
Alright, and I believe that brings us to the final question. When we look at your net interest-bearing debt, it stands at roughly 1.5 billion, which is 2 times EBITDA, and your covenants are around 3.5, if I'm not mistaken. So how much headroom is there really for the next acquisition, and is the pipeline still active, or are you devoting most of your time to Idé-Pro and OGM right now?
We're handling both at once. Our attention is on bringing Idé-Pro and OGM together, and beyond that we're naturally reviewing the pipeline to find fresh opportunities going forward. The debt level we currently carry feels like a comfortable place to be, yet we likewise see room for additional acquisitions.
Alright, thank you. That was the final question. Lars and Allan, many thanks for being with us today.
Thank you. Thank you to all of you who has been listening in.
Yes, this is also from me — thanks a lot, and I appreciate the questions here. I just want to wish you a good day and evening. Thank you.
Thank you.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete SP Group A/S transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to SP Group A/S earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.